{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:14:19Z","timestamp":1793222059583,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Peripheral blood immuno-inflammatory biomarkers (IIBs) may help predict response to neoadjuvant chemotherapy (NAC) and prognosis in HER2-positive breast cancer. This study compared the predictive value of neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) for pathological complete response (pCR) and disease-free survival (DFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A total of 224 female patients with HER2-positive invasive breast cancer who received NAC followed by surgery at two medical centers (2015\u20132023) were retrospectively analyzed. Baseline IIBs were calculated from complete blood counts. Receiver operating characteristic (ROC) curves identified optimal cut-offs. Logistic and Cox regression analyses combined with the least absolute shrinkage and selection operator (LASSO) method were used to determine factors associated with pCR and DFS. Subgroup analyses were performed to assess consistency across clinical and treatment variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SII demonstrated the highest discriminatory ability among tested IIBs for predicting pCR (AUC\u00a0=\u00a00.739) and was significantly associated with longer DFS (P\u00a0&amp;lt; 0.001). Patients with low SII had higher pCR rates and improved DFS. These associations remained stable across prespecified subgroups. Other factors related to better response included lower CA15-3\/CEA levels, \u22656 NAC cycles, receipt of HER2-targeted therapy, and breast-conserving surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among common inflammatory indices, SII demonstrated the strongest association with treatment response and prognosis in HER2-positive breast cancer. As an inexpensive, readily available biomarker, it may assist clinical risk stratification. However, given the retrospective design and substantial heterogeneity in treatment regimens, these findings should be interpreted cautiously and validated in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1751072","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:46:34Z","timestamp":1770623194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuanlin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mankai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longgui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102853","article-title":"Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer","volume":"132","author":"Bartsch","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","article-title":"Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in asia: The PEONY phase 3 randomized clinical trial","volume":"6","author":"Shao","year":"2020","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0158","article-title":"Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer","volume":"15","author":"Spring","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0916","article-title":"Neoadjuvant therapy as a platform for drug development and approval in breast cancer","volume":"19","author":"Bardia","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-024-08276-1","article-title":"The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy","volume":"637","author":"Bornes","year":"2025","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10549-011-1837-z","article-title":"Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review","volume":"132","author":"Luporsi","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2022.04.019","article-title":"Inflammatory burden as a prognostic biomarker for cancer","volume":"41","author":"Xie","year":"2022","journal-title":"Clin Nutr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.028","article-title":"A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study","volume":"47","author":"Proctor","year":"2011","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil\u2013lymphocyte ratio: Experience in patients with cancer","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2281","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals","volume":"8","author":"Guo","year":"2019","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1186\/s12885-020-07700-9","article-title":"Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13643-022-02123-y","article-title":"Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: A meta-analysis","volume":"11","author":"Zeng","year":"2022","journal-title":"Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275033","article-title":"Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231212184","article-title":"Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus bevacizumab","volume":"15","author":"Passardi","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00889-y","article-title":"Systemic immune-inflammation index\u00a0and\u00a0the survival of hepatocellular carcinoma patients after transarterial chemoembolization: A meta-analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4577-x","article-title":"Validation of the 8th AJCC prognostic staging system for\u00a0breast cancer in a population-based setting","volume":"168","author":"Abdel-Rahman","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of american pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: Updated recommendations from the international Ki67 in breast cancer working group","volume":"113","author":"Nielsen","year":"2021","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41419-022-04585-3","article-title":"Tumour cell apoptosis modulates the colorectal cancer immune microenvironment via interleukin-8-dependent neutrophil recruitment","volume":"13","author":"Schimek","year":"2022","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: Organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis","volume":"19","author":"Ethier","year":"2017","journal-title":"Breast Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12967-023-03924-y","article-title":"Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: A systematic review and meta-analysis","volume":"21","author":"Meng","year":"2023","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00580","article-title":"Prognostic value of preoperative systemic immune-inflammation index in breast cancer: A propensity score-matching study","volume":"10","author":"Hua","year":"2020","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12935-020-01308-6","article-title":"Prognostic value of the systemic immune-inflammation index in patients with breast cancer: A meta-analysis","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: From discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2513","article-title":"Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer","volume":"30","author":"Tan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.135566","article-title":"Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer","volume":"56","author":"Molina","year":"2010","journal-title":"Clin Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30067-5","article-title":"10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: A population-based study","volume":"17","author":"van Maaren","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:46:36Z","timestamp":1770623196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1751072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1751072"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1751072","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1751072"}}